Just Out " How Provenge Can Capitalize On The Enormous Prostate Cancer Market." LINK
Dendreon: The Opportunity for Investors
By David Williamson and Austin Smith | More Articles | Save For Later
January 10, 2013 | Comments (0)
Although Dendreon's (NASDAQ: DNDN ) performance hasn't met lofty investor expectations, there is still real reason to be excited. In this video, Motley Fool health care analyst David Williamson discusses Dendreon's potentially revolutionary prostate cancer vaccine, Provenge, and how it can capitalize on the enormous prostate cancer market.